Skip to content
10-Q

Quarterly Report

ENTASIS THERAPEUTICS HOLDINGS INC.

0001558370-21-014453

← back to feed
Filed
Nov 4, 2021 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Nov 1, 2021 47.64M sh
Capex Q3 2021 · Sep 30, 2021 $70K
Operating Cash Flow Q3 2021 · Sep 30, 2021 −$30.68M
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$37.71M
Cash And Equivalents Q3 2021 · Sep 30, 2021 $44.12M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $53.25M
Stockholders Equity Q3 2021 · Sep 30, 2021 $41.24M
Stockholders Equity Q3 2021 · Jun 30, 2021 $53.06M
Stockholders Equity Q3 2021 · Dec 31, 2020 $52.29M
Stockholders Equity Q3 2021 · Sep 30, 2020 $62.24M
Stockholders Equity Q3 2021 · Jun 30, 2020 $49.29M
Stockholders Equity Q3 2021 · Dec 31, 2019 $42.16M
Current Liabilities Q3 2021 · Sep 30, 2021 $9.35M
Current Liabilities Q3 2021 · Dec 31, 2020 $8.57M
Total Liabilities Q3 2021 · Sep 30, 2021 $9.53M
Total Liabilities Q3 2021 · Dec 31, 2020 $9.27M
Current Assets Q3 2021 · Sep 30, 2021 $49.75M
Current Assets Q3 2021 · Dec 31, 2020 $60.13M
Total Assets Q3 2021 · Sep 30, 2021 $50.77M
Total Assets Q3 2021 · Dec 31, 2020 $61.56M
Sga Expense Q3 2021 · Sep 30, 2021 $4.32M
Sga Expense Q3 2021 · Sep 30, 2021 $10.94M
Sga Expense Q3 2021 · Sep 30, 2020 $3.21M
Sga Expense Q3 2021 · Sep 30, 2020 $10.24M
Rd Expense Q3 2021 · Sep 30, 2021 $9.28M
Rd Expense Q3 2021 · Sep 30, 2021 $28.64M
Rd Expense Q3 2021 · Sep 30, 2020 $9.39M
Rd Expense Q3 2021 · Sep 30, 2020 $31.25M
Net Income Q3 2021 · Sep 30, 2021 −$12.39M
Net Income Q3 2021 · Sep 30, 2021 −$35.12M
Net Income Q3 2021 · Sep 30, 2020 −$11.13M
Net Income Q3 2021 · Sep 30, 2020 −$39.8M
Operating Income Q3 2021 · Sep 30, 2021 −$13.6M
Operating Income Q3 2021 · Sep 30, 2021 −$39.58M
Operating Income Q3 2021 · Sep 30, 2020 −$12.6M
Operating Income Q3 2021 · Sep 30, 2020 −$41.48M